B2M and plasma cell myeloma: Furthermore, the fully adjusted model, including age, gender, eGFR, HB, LDH, RI, albumin, serum/urinary lambda or kappa light chains, serum beta 2-microglobulin, and anti-myeloma therapy regimen showed that the patients in the L group had a significantly higher risk for the development of ESRD compared with the M group.